{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:57:44Z","timestamp":1783065464743,"version":"3.54.6"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Research Fund of the Health Agency of Zhejiang Province","award":["No.2016KYB100"],"award-info":[{"award-number":["No.2016KYB100"]}]},{"name":"the Zhejiang Provincial Natural Science Foundation of China","award":["No.LY19H020008"],"award-info":[{"award-number":["No.LY19H020008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>High risk of embolic events exists in both patients with chronic atrial fibrillation (AF) and patients in the perioperative period of ablation (effective treatment for AF). Therefore, anticoagulant therapy is important. Oral anticoagulants can be divided into two major categories: vitamin K antagonists (VKAs) and non-vitamin K antagonist oral anticoagulants (NOACs). VKAs, represented by warfarin, have been widely used as traditional anticoagulants, whereas NOACs have been used in clinical practice, but their anticoagulant effects and side effects are still the focus of research. We used a meta-analysis to compare the incidence of left atrial thrombi (LAT) between different anticoagulants.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We searched PubMed, EMBASE, Web of Science, and the Cochrane Library databases for observational studies that compared the transesophageal echocardiography (TEE) findings for patients treated with NOACs and VKAs. The incidence of LAT and <jats:italic>dense spontaneous echocardiographic contrast (dense SEC)<\/jats:italic> were extracted as the basis of the meta-analysis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Fifteen studies were included in the meta-analysis. We found that patients anticoagulated with NOACs and VKAs had similar incidence of LAT (OR\u2009=\u20090.74, 95%CI: 0.55\u20131.00). After excluding the heterogeneous article by sensitivity analysis, we found the incidence of LAT in patients anticoagulated with NOACs is lower than VKAs (OR\u2009=\u20090.59, 95%CI: 0.42\u20130.84). The results of subgroup analysis showed that the incidence of LAT among three types of NOACs have no significant difference (dabigatran vs. rivaroxaban, OR\u2009=\u20091.16 [0.75, 1.81]; rivaroxaban vs. apixaban, OR\u2009=\u20090.97 [0.54, 1.74]; dabigatran vs. apixaban, OR\u2009=\u20091.09 [0.55, 2.16]).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Patients anticoagulated with NOACs may have lower incidence of LAT than VKAs. The incidence of LAT among different type of NOACs are similar.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12872-019-1209-x","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T08:03:02Z","timestamp":1574755382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of transesophageal echocardiography findings after different anticoagulation strategies in patients with atrial fibrillation: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Jian","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-zan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9636-177X","authenticated-orcid":false,"given":"Shen-Jiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"issue":"11","key":"1209_CR1","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1161\/STROKEAHA.113.002329","volume":"44","author":"S Bjorck","year":"2013","unstructured":"Bjorck S, Palaszewki B, Friberg L, et al. Atrial fibrillation, stroke risk, and warfarin in therapy revisited: a population-based study. Stroke. 2013;44(11):3103\u20138.","journal-title":"Stroke"},{"issue":"5","key":"1209_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","volume":"113","author":"S Stewart","year":"2002","unstructured":"Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study. Am J Med. 2002;113(5):359\u201364.","journal-title":"Am J Med"},{"issue":"2","key":"1209_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1161\/STROKEAHA.113.003433","volume":"45","author":"A Kishore","year":"2014","unstructured":"Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45(2):520\u20136.","journal-title":"Stroke"},{"issue":"4","key":"1209_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1747-4949.2011.00706.x","volume":"7","author":"KM Henriksson","year":"2012","unstructured":"Henriksson KM, Farahmand B, Asberg S, et al. Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. Int J Stroke. 2012;7(4):276\u201381.","journal-title":"Int J Stroke"},{"issue":"12","key":"1209_CR5","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1161\/STROKEAHA.113.001884","volume":"44","author":"M Grond","year":"2013","unstructured":"Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke. 2013;44(12):3357\u201364.","journal-title":"Stroke"},{"issue":"3","key":"1209_CR6","first-page":"72","volume":"53","author":"IV Zotova","year":"2013","unstructured":"Zotova IV, Zateishchikov DA, Sidorenko BA. Mechanisms of development of thromboembolic complications in patients with atrial fibrillation. Kardiologiia. 2013;53(3):72\u201380.","journal-title":"Kardiologiia"},{"issue":"24","key":"1209_CR7","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1016\/j.jacc.2015.04.025","volume":"65","author":"DR Holmes Jr","year":"2015","unstructured":"Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65(24):2614\u201323.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1209_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857\u201367.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1209_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/europace\/euu225","volume":"17","author":"JB Olesen","year":"2015","unstructured":"Olesen JB, Sorensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant na\u00efve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace. 2015;17(2):187\u201393.","journal-title":"Europace"},{"issue":"9921","key":"1209_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383(9921):955\u201362.","journal-title":"Lancet"},{"issue":"4","key":"1209_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2174\/187152906779010728","volume":"6","author":"S Ali","year":"2006","unstructured":"Ali S, Hong M, Antezano ES, et al. Evaluation and management of atrial fibrillation. Cardiovasc Hematol Disord Drug Targets. 2006;6(4):233\u201344.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"1209_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijcard.2018.04.034","volume":"268","author":"N Telles Garcia","year":"2018","unstructured":"Telles Garcia N, Dahal K, Kocherla C, et al. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2018;268:143\u20138.","journal-title":"Int J Cardiol"},{"issue":"11","key":"1209_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/europace\/euw295","volume":"18","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609\u201378.","journal-title":"Europace"},{"issue":"2","key":"1209_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","volume":"61","author":"JL Blackshear","year":"1996","unstructured":"Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Tohrac Surg. 1996;61(2):755\u20139.","journal-title":"Ann Tohrac Surg"},{"key":"1209_CR15","volume-title":"Cochrane handbook for systematic reviews of interventions","year":"2011","unstructured":"Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. New York: Wiley; 2011."},{"key":"1209_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181fe7825","volume":"22","author":"D Moher","year":"2011","unstructured":"Moher D, Altman DG, Liberati A, Tetzlaff J. PRISMA statement. Epidemiology. 2011;22:128.","journal-title":"Epidemiology"},{"issue":"1","key":"1209_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/europace\/euy129","volume":"21","author":"W Alqarawi","year":"2019","unstructured":"Alqarawi W, Birnie DH, Spence S, et al. Prevalence of left atrial appendage thrombus detected by transoesophageal echocardiography before catheter ablation of atrial fibrillation in patients anticoagulated with non-vitamin K antagonist oral anticoagulants. Europace. 2019;21(1):48\u201353.","journal-title":"Europace"},{"issue":"4","key":"1209_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/jce.13447","volume":"29","author":"B Schaeffer","year":"2018","unstructured":"Schaeffer B, Ruden L, Salzbrunn T, et al. Incidence of intracardiac thrombus formation prior to electrical cardioversion in respect to the mode of oral anticoagulation. J Cardiovasc Electrophysiol. 2018;29(4):537\u201347.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"1209_CR19","doi-asserted-by":"publisher","first-page":"e0191648","DOI":"10.1371\/journal.pone.0191648","volume":"13","author":"YG Kim","year":"2018","unstructured":"Kim YG, Chi JI, Kim MN, et al. Non-vitamin K antagonist oral anticoagulants versus warfarin for the prevention of spontaneous echo-contrast and thrombus in patients with atrial fibrillation or flutter undergoing cardioversion: a trans-esophageal echocardiography study. PLoS One. 2018;13(1):e0191648.","journal-title":"PLoS One"},{"issue":"2","key":"1209_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11239-017-1599-5","volume":"45","author":"V Russo","year":"2018","unstructured":"Russo V, Rago A, Papa AA, et al. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. J Thromb Thrombolysis. 2018;45(2):206\u201312.","journal-title":"J Thromb Thrombolysis"},{"key":"1209_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ahj.2017.07.016","volume":"193","author":"A Da Costa","year":"2017","unstructured":"Da Costa A, Delolme C, Guichard JB, et al. Comparison of prevalence and management of left atrial appendage thrombi under old and new anticoagulants prior to left atrial catheter ablation. Am Heart J. 2017;193:8\u201315.","journal-title":"Am Heart J"},{"issue":"12","key":"1209_CR22","first-page":"823","volume":"127","author":"M Gawalko","year":"2017","unstructured":"Gawalko M, Kaplon-Cieslicka A, Budnik M, et al. Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion. Pol Arch Intern Med. 2017;127(12):823\u201331.","journal-title":"Pol Arch Intern Med"},{"issue":"5","key":"1209_CR23","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1097\/MJT.0000000000000590","volume":"24","author":"D Tint","year":"2017","unstructured":"Tint D, Petris AO, Pop I, et al. Vitamin K antagonists versus novel oral anticoagulants for elective electrical cardioversion of atrial fibrillation. Am J Ther. 2017;24(5):e553\u20138.","journal-title":"Am J Ther"},{"issue":"10","key":"1209_CR24","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/jce.13279","volume":"28","author":"MA Gunawardene","year":"2017","unstructured":"Gunawardene MA, Dickow J, Schaeffer BN, et al. Risk stratification of patients with left atrial appendage thrombus prior to catheter ablation of atrial fibrillation: an approach towards an individualized use of transesophageal echocardiography. J Cardiovasc Electrophysiol. 2017;28(10):1127\u201336.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"1209_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12872-017-0503-8","volume":"17","author":"J Barysiene","year":"2017","unstructured":"Barysiene J, Zebrauskaite A, Petrikonyte D, et al. Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion. BMC Cardiovasc Disord. 2017;17(1):67.","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"1209_CR26","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1253\/circj.CJ-16-1089","volume":"81","author":"M Kawabata","year":"2017","unstructured":"Kawabata M, Goya M, Sasaki T, et al. Left atrial appendage thrombi formation in Japanese non-valvular atrial fibrillation patients during anticoagulation therapy - warfarin vs. direct oral anticoagulants. Circ J. 2017;81(5):645\u201351.","journal-title":"Circ J"},{"issue":"7","key":"1209_CR27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.amjcard.2016.12.008","volume":"119","author":"J Wyrembak","year":"2017","unstructured":"Wyrembak J, Campbell KB, Steinberg BA, et al. Incidence and predictors of left atrial appendage thrombus in patients treated with nonvitamin K oral anticoagulants versus warfarin before catheter ablation for atrial fibrillation. Am J Cardiol. 2017;119(7):1017\u201322.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1209_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40001-016-0235-8","volume":"21","author":"S Reers","year":"2016","unstructured":"Reers S, Agdirlioglu T, Kellner M, et al. Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists. Eur J Med Res. 2016;21(1):41.","journal-title":"Eur J Med Res"},{"issue":"3","key":"1209_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacep.2016.01.004","volume":"2","author":"D Frenkel","year":"2016","unstructured":"Frenkel D, D\u2019Amato SA, AI-Kazaz M, et al. Prevalence of left atrial thrombus detection by transesophageal echocardiography: a comparison of continuous non-vitamin K antagonist oral anticoagulant versus warfarin therapy in patients undergoing catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2016;2(3):295\u2013303.","journal-title":"JACC Clin Electrophysiol"},{"issue":"4","key":"1209_CR30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.hrthm.2017.12.005","volume":"15","author":"M Wu","year":"2018","unstructured":"Wu M, Gabriels J, Khan M, et al. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: comparison of dabigatran, rivaroxaban, and apixaban. Heart Rhythm. 2018;15(4):496\u2013502.","journal-title":"Heart Rhythm"},{"key":"1209_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2017.07.048","volume":"249","author":"E Bertaglia","year":"2017","unstructured":"Bertaglia E, Anselmino M, Zorzi A, et al. NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world. Int J Cardiol. 2017;249:179\u201383.","journal-title":"Int J Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-019-1209-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-019-1209-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-019-1209-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:27:33Z","timestamp":1606264053000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-019-1209-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1186\/s12872-019-1209-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]},"assertion":[{"value":"17 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}